Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2018
This report can be delivered to the clients within 24 hours
'Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2018', report provides comprehensive Insight about pipeline drugs along with technologies involved across this Cell Therapy. The report provides the detailed analysis of 30+ products along with 20+ companies involved. The report also covers a separate section for the Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. European Commission has granted Orphan Drug Designation to IPH4102 for the treatment of Cutaneous T-Cell Lymphoma.
Products covered by Phase
Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Natural Killer Cell Therapies
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Cell Therapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
'Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2018', report provides comprehensive Insight about pipeline drugs along with technologies involved across this Cell Therapy. The report provides the detailed analysis of 30+ products along with 20+ companies involved. The report also covers a separate section for the Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. European Commission has granted Orphan Drug Designation to IPH4102 for the treatment of Cutaneous T-Cell Lymphoma.
Products covered by Phase
- Phase II and Phase I
- Pre-clinical
Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Natural Killer Cell Therapies
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Cell Therapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
- The report provides competitive pipeline landscape of Natural Killer Cell Therapies
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Natural Killer Cell Therapies
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Natural Killer Cell Therapies pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Natural Killer Cell Therapies and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from mid stage till preclinical stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Establish a comprehensive understanding of the current pipeline scenario across Natural Killer Cell Therapies to formulate effective R&D strategies
- Assess challenges and opportunities that influence Natural Killer Cell Therapies R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Devise corrective measures for pipeline projects by understanding Natural Killer Cell Therapies pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Natural Killer Cell Therapies to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
- Gaining a full picture of the Competitive Landscape for Evidence based Decisions
Natural Killer Cells Therapy Overview
Natural Killer (NK) Cells
Mechanism of Action of NK-cells
NK Cells in Cancer
NK Cell Therapies
Types of NK-based Immunotherapy
Natural Killer Cell Therapies
Natural Killer Cell Therapies and Targets
Targets and Number of Products
Collaborations& Licensing Agreements for NK Cells Therapy
Collaborations and Deal values
Licensing Agreement for Future Developments
Financing details of NK cell Therapies
Designation
Institutes involved in NK cell Therapies
Technologies for NK Cell Therapies
Pipeline Therapeutics for Natural Killer Cell Therapies
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
MG 4101: Green Cross Corporation
Product Description
Research and Development
Product Development Activities
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment of Natural Killer Cell Therapies
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NK Cells Based Prophylaxis
Cancer Breakthrough Program 2020
Natural Killer Cell Augmenters
Number of NK cell Augmenters by Targets
Collaborations for NK Cells Augmenters
Collaborations and Deal value
Licensing Agreement for future development of NK Cell Augmenters
Financing Details of NK Cells Augmenters
Grants Received by Companies for NK Cells Augmenters
Designation
Institutes involved in NK Cells Augmenters Based Therapies
Pipeline Therapeutics for Natural Killer Cells Augmenters
Therapeutics under Development by Companies
NK Cells Enhancers
NK Cells Activators
Natural Killer Cell Enhancers
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre –clinical Stage Products
Comparative Analysis
Natural Killer Cell Activators
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre–clinical Stage Products
Comparative Analysis
Therapeutic Assessment of Natural Killer Cell Augmenters (Enhancers & Activators)
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Market Drivers
Market Barriers
SWOT Analysis
Appendix
Natural Killer (NK) Cells
Mechanism of Action of NK-cells
NK Cells in Cancer
NK Cell Therapies
Types of NK-based Immunotherapy
Natural Killer Cell Therapies
Natural Killer Cell Therapies and Targets
Targets and Number of Products
Collaborations& Licensing Agreements for NK Cells Therapy
Collaborations and Deal values
Licensing Agreement for Future Developments
Financing details of NK cell Therapies
Designation
Institutes involved in NK cell Therapies
Technologies for NK Cell Therapies
Pipeline Therapeutics for Natural Killer Cell Therapies
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
MG 4101: Green Cross Corporation
Product Description
Research and Development
Product Development Activities
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment of Natural Killer Cell Therapies
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NK Cells Based Prophylaxis
Cancer Breakthrough Program 2020
Natural Killer Cell Augmenters
Number of NK cell Augmenters by Targets
Collaborations for NK Cells Augmenters
Collaborations and Deal value
Licensing Agreement for future development of NK Cell Augmenters
Financing Details of NK Cells Augmenters
Grants Received by Companies for NK Cells Augmenters
Designation
Institutes involved in NK Cells Augmenters Based Therapies
Pipeline Therapeutics for Natural Killer Cells Augmenters
Therapeutics under Development by Companies
NK Cells Enhancers
NK Cells Activators
Natural Killer Cell Enhancers
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre –clinical Stage Products
Comparative Analysis
Natural Killer Cell Activators
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre–clinical Stage Products
Comparative Analysis
Therapeutic Assessment of Natural Killer Cell Augmenters (Enhancers & Activators)
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Market Drivers
Market Barriers
SWOT Analysis
Appendix
LIST OF TABLES
Table 1: Targets and Number of Products
Table 2: Collaboration and Deal Values
Table 3: Licensing Agreement for future development of NK Cell based Therapy
Table 4: Companies of NK cell based therapies financing for future developments
Table 5: Analysis of Natural Killer Cell Therapies On The Basis of Designation
Table 6: Institutes involved in NK Cell Therapies
Table 7:Companies and their Technologies for NK Cell Therapies
Table 8:Number of Products Under Development for Natural Killer Cell Therapies
Table 9: Number of Products under development by Companies
Table 10: Mid Stage Products (Phase II)
Table 11: Early Stage Products (Phase I)
Table 12: Pre-clinical and Discovery Stage Products
Table 13: Assessment by Monotherapy Products
Table 14: Assessment by Route of Administration
Table 15:Assessment by Stage and Route Of Administration
Table 16: Assessment by Molecule Type
Table 17: Assessment by Stage and Molecule Type
Table 18: Number of Products by Targets
Table 19: Collaboration and Deal Values for NK cell Augmenters
Table 20: Licensing Agreement for future development of NK Cell Augmenters Therapy
Table 21: Financing Details of NK Cells Augmenters
Table 22: Grants Received by Companies of NK Cells Augmenters
Table 23: Analysis of Natural Killer Cells Augmenters On The Basis of Designation
Table 24: Institutes involved in NK Cells Augmenters
Table 25: Technologies for NK Cell Augmenters
Table 26: Number of Products Under Development for Natural Killer Cells Augmenters
Table 27: Number of Products under development by Companies
Table 28: Number of Products under development by Companies
Table 29: Mid Stage Products (Phase II)
Table 30: Early Stage Products (Phase I)
Table 31: Pre-clinical Stage Products
Table 32: Mid Stage Products (Phase II)
Table 33: Early Stage Products (Phase I and IND)
Table 34: Assessment by Monotherapy Products
Table 35: Assessment by Route of Administration
Table 36: Assessment by Stage and Route of Administration
Table 37: Assessment by Molecule Type
Table 38: Assessment by Stage and Molecule Type
Table 1: Targets and Number of Products
Table 2: Collaboration and Deal Values
Table 3: Licensing Agreement for future development of NK Cell based Therapy
Table 4: Companies of NK cell based therapies financing for future developments
Table 5: Analysis of Natural Killer Cell Therapies On The Basis of Designation
Table 6: Institutes involved in NK Cell Therapies
Table 7:Companies and their Technologies for NK Cell Therapies
Table 8:Number of Products Under Development for Natural Killer Cell Therapies
Table 9: Number of Products under development by Companies
Table 10: Mid Stage Products (Phase II)
Table 11: Early Stage Products (Phase I)
Table 12: Pre-clinical and Discovery Stage Products
Table 13: Assessment by Monotherapy Products
Table 14: Assessment by Route of Administration
Table 15:Assessment by Stage and Route Of Administration
Table 16: Assessment by Molecule Type
Table 17: Assessment by Stage and Molecule Type
Table 18: Number of Products by Targets
Table 19: Collaboration and Deal Values for NK cell Augmenters
Table 20: Licensing Agreement for future development of NK Cell Augmenters Therapy
Table 21: Financing Details of NK Cells Augmenters
Table 22: Grants Received by Companies of NK Cells Augmenters
Table 23: Analysis of Natural Killer Cells Augmenters On The Basis of Designation
Table 24: Institutes involved in NK Cells Augmenters
Table 25: Technologies for NK Cell Augmenters
Table 26: Number of Products Under Development for Natural Killer Cells Augmenters
Table 27: Number of Products under development by Companies
Table 28: Number of Products under development by Companies
Table 29: Mid Stage Products (Phase II)
Table 30: Early Stage Products (Phase I)
Table 31: Pre-clinical Stage Products
Table 32: Mid Stage Products (Phase II)
Table 33: Early Stage Products (Phase I and IND)
Table 34: Assessment by Monotherapy Products
Table 35: Assessment by Route of Administration
Table 36: Assessment by Stage and Route of Administration
Table 37: Assessment by Molecule Type
Table 38: Assessment by Stage and Molecule Type
LIST OF FIGURES
Figure 1: Mechanism of action
Figure 2: Analysis of Natural Killer Cell Therapies On The Basis of Designation
Figure 3: Number of Products under Development for Natural Killer Cell Therapies
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I)
Figure 6: Pre-clinical and Discovery Stage Products
Figure 7: Assessment by Monotherapy Products
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: NK Cells Augmenters based therapies designation and Number of Products
Figure 13: Number of Products under Development for Natural Killer Cells Augmenters
Figure 14: Mid Stage Products (Phase II)
Figure 15: Early Stage Products (Phase I)
Figure 16: Pre-clinical Stage Products
Figure 17: Mid Stage Products (Phase II)
Figure 18: Early Stage Products (Phase I and IND)
Figure 19: Pre–clinical Stage Stage Products
Figure 20: Assessment by Monotherapy Products
Figure 21: Assessment by Route of Administration
Figure 22: Assessment by Stage and Route of Administration
Figure 23: Assessment by Molecule Type
Figure 24: Assessment by Stage and Molecule Type
Figure 1: Mechanism of action
Figure 2: Analysis of Natural Killer Cell Therapies On The Basis of Designation
Figure 3: Number of Products under Development for Natural Killer Cell Therapies
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I)
Figure 6: Pre-clinical and Discovery Stage Products
Figure 7: Assessment by Monotherapy Products
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: NK Cells Augmenters based therapies designation and Number of Products
Figure 13: Number of Products under Development for Natural Killer Cells Augmenters
Figure 14: Mid Stage Products (Phase II)
Figure 15: Early Stage Products (Phase I)
Figure 16: Pre-clinical Stage Products
Figure 17: Mid Stage Products (Phase II)
Figure 18: Early Stage Products (Phase I and IND)
Figure 19: Pre–clinical Stage Stage Products
Figure 20: Assessment by Monotherapy Products
Figure 21: Assessment by Route of Administration
Figure 22: Assessment by Stage and Route of Administration
Figure 23: Assessment by Molecule Type
Figure 24: Assessment by Stage and Molecule Type
